お知らせ －information
Contact Form Issue Resolved
We have identified that there was a period during which the “Contact Us” form on our website may not have been functioning properly, and inquiries may not have been successfully submitted.
Period of the issue:
After the website renewal: January 8, 2026 – January 27, 2026
We sincerely apologize for any inconvenience this may have caused to those who used our website.
The issue has now been resolved, and the “Contact Us” form is currently functioning normally.
If you submitted an inquiry during the above period and have not received a response from us, we kindly ask that you contact us again at the email address below.
We appreciate your understanding.
Launch of SunShell Peptide C9 and SunShell Protein C8
ChromaNik Technologies has launched SunShell Peptide C9 and SunShell Protein C8, new bio-molecule-oriented columns designed to improve separation performance and reproducibility of peptides and proteins in LC-MS analysis.
The specifications are as follows.
SunShell Peptide C9
Particle size: 2.6 μm (core diameter: 1.6 μm)
Pore size: 16 nm
Carbon load: 2.5%
Bonded phase: Hexafunctional C18
Inertization:
Sunniest end-capping + proprietary advanced inert treatment to suppress non-specific adsorption
Feature:
- By reducing the carbon load to half while maintaining the same base material and bonding density as SunShell Peptide C18, this column provides distinct selectivity and alternative separation behavior.
- The introduction of a multifunctional bonding chemistry significantly enhances acid stability.
SunShell Protein C8
Particle size: 3.4 μm (core diameter: 3.0 μm)
Pore size: 16 nm
Carbon load: 0.5%
Bonded phase: C8
Inertization:
Sunniest end-capping + proprietary advanced inert treatment to suppress non-specific adsorption
Feature:
- This column employs a balanced design combining thin porous-shell core-shell particles and a wide-pore substrate, enabling both effective separation and smooth elution of proteins.
- Advanced end-capping ensures compatibility with high-temperature operating conditions.
These columns are derivative products of the SunShell Peptide C18, launched in 2024, and are manufactured using the same advanced inertization technology.
By effectively minimizing adsorption, they support LC-MS analysis across a broad range of targets, from moderately to highly hydrophobic peptides and proteins.
For full details on the SunShell Peptide C18 series lineup and pricing, please refer to the dedicated brochure [PDF].
Thank you for your continued interest.
Added Aplication Data(No.1209-1220)
We are pleased to announce that new application data has been added.
Most of the data were generated using the new high-durability HPLC column SunBridge, launched in February 2025.
1220 Polysaccharides (galactan)
1219 ABEE-derivatized sugars
1218 Quercetin glycosides
1217 Coproporphyrin I
1216 Bile Acids and PFOS (a key PFAS) in SRM1958
1215 Bile Acids and PFOS (a key PFAS) in umbilical cord blood
1214 Bile Acids and PFOS (a key PFAS)
1213 Capsaicin in Chili Peppers
1212 Catechins (4)
1211 Sterols
1210 Fluorobenzene and benzene (3)
1209 Oligonucleotide(2)
SunBridge C18(sub-2µm) and PFP-R Launch
In addition to the launch of the SunBridge platform, ChromaNik Technologies is pleased to announce the release of two new product lines: SunBridge C18 (1.8 µm, 3 µm) and SunBridge PFP-R (3 µm).
The SunBridge series, developed based on unique Ultra-Hybrid Technology, is an organosilica column first introduced to the market in February 2025.
The SunBridge C18 columns, available in both sub-2 µm and 3 µm particle sizes, deliver outstanding efficiency and reproducibility for high-resolution separations, making them ideally suited for both UHPLC and conventional HPLC systems.
For more details and specifications, refer to the brochure[PDF] and the poster[PDF] provided.
The SunBridge PFP-R (3 µm) column introduces enhanced selectivity for fluorinated compounds (including both short- and long-chain PFAS), aromatic isomers, and polar analytes, offering unique retention characteristics that complement traditional C18 phases.
For more details and specifications, refer to the brochure[PDF] and the PFAS poster[PDF] provided.
With these new additions, the SunBridge series further extends its versatility, enabling researchers and analysts to address a wider range of separation challenges with confidence.
SunBridge C18 3µm Now Launched
SunBridge C18 5 µm, featuring exceptional alkaline durability enabled by Ultra Hybrid Technology, was launched in February 2025.
Subsequently, SunBridge C18 3 µm was launched in April 2025.
SunBridge C18 3 µm is effective for improving separation performance and ensuring stable operation in oligonucleotide analysis under high-temperature and high-pH conditions.
Fig. Part of Application No. 1209: Oligonucleotide (2) using SunBridge C18 3 µm [PDF]
For more details, please visit the dedicated page.
